Cookies on Animal Science Database

Like most websites we use cookies. This is to ensure that we give you the best experience possible.

Continuing to use means you agree to our use of cookies. If you would like to, you can learn more about the cookies we use.

News Article

CYTOPOINT® - The first monoclonal antibody therapy for canine atopic dermatitis launched by Zoetis

This new therapeutic is designed to interrupt the itch cycle, allowing dogs to stop scratching so damaged skin can heal.

CYTOPOINT® is a monoclonal antibody (mAb) that specifically targets and neutralises canine interleukin 31 (cIL-31), an important cytokine involved in sending the itch signal to the brain in atopic dermatitis.

Interleukin 31 (IL-31) is a cytokine that triggers the process of sending itch signals to the brain and mAb is a single, homogenous antibody preparation cloned from a single lineage of B cells, which is designed to mimic a normal immune function by recognising and binding to one single segment, or epitope, on a particular target antigen.

CYTOPOINT® is highly targeted to a specific cytokine involved in canine atopic dermatitis, and therefore has a minimal impact on normal immune functions. It functions like naturally occurring antibodies and is eliminated through the process of catabolism, in the same way as normal protein degradation pathways, with minimal involvement of the liver and kidneys.

The safety and efficacy of CYTOPOINT® were demonstrated in clinical trials up to 9 months in duration, according to Zoetis. In rare cases, hypersensitivity reactions (anaphylaxis, facial oedema, urticaria) may occur. In such cases, appropriate treatment should be administered without delay.

CYTOPOINT® was shown to have minimal side effects when administered to laboratory Beagles at up to 10 times the label dose (10 mg/kg) monthly for 7 months. No treatment effects on clinical observations or clinical pathology were identified. It has no known drug interactions — minimal side effects in combination with commonly used medications, including oclacitinib tablet, corticosteroids, cyclosporine and antihistamines. Treatments such as endo- and ectoparasiticides, antimicrobials, anti-inflammatories and vaccines may be given on the day of treatment, but any vaccine given at the same time as CYTOPOINT® should be administered at a different injection site. No age restrictions.

CYTOPOINT® contains no preservatives and vials are intented for single subcutaneous use only. The recommended minimum dose is 1 mg/kg body weight, once a month.


1.CYTOPOINT® Summary of Product Characteristics.

2.Gonzales A J, Humphrey WR, Messamore JE, et al. Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis. Vet Dermatol. 2013; 24 (1): 48−53. doi:l0.1111/j.1365-3164.2012.01098.x.

3. Olivry T, Bainbridge G. Clinician’s Brief. Advances in veterinary medicine: therapeutic monoclonal antibodies for companion animals. March 2015. Accessed June 21, 2016.

4.Greenfield EA. Generating monoclonal antibodies. In: Greenfield EA , ed. Antibodies: A Laboratory Manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2014: 201−221.

5.Gonzales A J, Bowman JW, Fici GJ, et al. Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther. 2014; 37(4): 317−324. doi:10.1111/jvp.12101.

6. Marsella R, Sousa CA , Gonzales A J, Fadok VA . Current understanding of the pathophysiologic mechanisms of canine atopic dermatitis. J. Am. Vet. Med. Assoc. 2012; 241 (2): 194-207. doi:10.2460/javma.241.2.194.

7. Olivry T, DeBoer DJ, Favrot C, et al. Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. Vet. Dermatol. 2010; 21 (3): 233-248. doi:10.1111/j.1365-3164.2010.00889.x.

8. Data on file, Study Report No. C866C-XC-13-056, Zoetis Inc.

9. Data on file, Study Report No. C866C-XC-14-082, Zoetis Inc.

10. Data on file, Study Report No. C362N-US-13-042, Zoetis Inc.

11. Michels GM, Walsh KF, Kryda KA, et al. A blinded, randomized, placebo-controlled trial of the safety of lokivetmab (ZTS-00103289), a caninized anti-canine IL-31 monoclonal antibody in client-owned dogs with atopic dermatitis. Vet Dermatol. 2016; 27 (6): 505−e136. doi:10.1111/vde.12364.

12. Data on file, Study Report No. C961R-US-13-051, Zoetis Inc.

Contact: Zoetis, Walton Oaks, Dorking Road, Tadworth, Surrey, KT20 7NS, UK, Web: Tel: 0845 300 8034, or from Zoetis Ireland Ltd, 9 Riverwalk, Citywest Business Campus, Dublin 24 POM, Ireland. 

Article details

  • Author(s)
  • M Djuric, DVM
  • Date
  • 13 September 2017
  • Source
  • Zoetis, UK
  • Subject(s)
  • Veterinary medicine